Your browser doesn't support javascript.
loading
A novel small molecule aurora kinase inhibitor attenuates breast tumor-initiating cells and overcomes drug resistance.
Zheng, Fei-Meng; Long, Zi-Jie; Hou, Zhi-Jie; Luo, Yu; Xu, Ling-Zhi; Xia, Jiang-Long; Lai, Xiao-Ju; Liu, Ji-Wei; Wang, Xi; Kamran, Muhammad; Yan, Min; Shao, Shu-Juan; Lam, Eric W-F; Wang, Shao-Wu; Lu, Gui; Liu, Quentin.
Afiliação
  • Zheng FM; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine; Institute of Cancer Stem Cell, Dalian Medical University; Institute of Cancer Stem Cell, Institute of Cancer Stem Cell - First Affiliated Hospital Collaborative
  • Long ZJ; Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University;
  • Hou ZJ; Institute of Cancer Stem Cell, Institute of Cancer Stem Cell - First Affiliated Hospital Collaborative Innovation Center of Oncology;
  • Luo Y; Institute of Medicinal Chemistry, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou;
  • Xu LZ; Institute of Cancer Stem Cell, Institute of Cancer Stem Cell - First Affiliated Hospital Collaborative Innovation Center of Oncology;
  • Xia JL; Institute of Cancer Stem Cell, Institute of Cancer Stem Cell - First Affiliated Hospital Collaborative Innovation Center of Oncology;
  • Lai XJ; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine; Institute of Cancer Stem Cell, Dalian Medical University;
  • Liu JW; Institute of Cancer Stem Cell, Institute of Cancer Stem Cell - First Affiliated Hospital Collaborative Innovation Center of Oncology;
  • Wang X; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine; Institute of Cancer Stem Cell, Dalian Medical University;
  • Kamran M; Institute of Cancer Stem Cell, Institute of Cancer Stem Cell - First Affiliated Hospital Collaborative Innovation Center of Oncology;
  • Yan M; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine; Institute of Cancer Stem Cell, Dalian Medical University;
  • Shao SJ; Department of Histology and Embryology, Dalian Medical University, Dalian, China; and.
  • Lam EW; Department of Surgery and Cancer, Imperial Centre for Translational and Experimental Medicine (ICTEM), Imperial College London, London, United Kingdom.
  • Wang SW; Institute of Cancer Stem Cell, Institute of Cancer Stem Cell - First Affiliated Hospital Collaborative Innovation Center of Oncology;
  • Lu G; Institute of Medicinal Chemistry, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou; liuq9@mail.sysu.edu.cn liuqiang@dlmedu.edu.cn lugui@mail.sysu.edu.cn.
  • Liu Q; Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine; Institute of Cancer Stem Cell, Dalian Medical University; Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University; Institute of Cancer Stem C
Mol Cancer Ther ; 13(8): 1991-2003, 2014 Aug.
Article em En | MEDLINE | ID: mdl-24899685
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Células-Tronco Neoplásicas / Neoplasias da Mama / Resistencia a Medicamentos Antineoplásicos / Antineoplásicos Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Células-Tronco Neoplásicas / Neoplasias da Mama / Resistencia a Medicamentos Antineoplásicos / Antineoplásicos Idioma: En Ano de publicação: 2014 Tipo de documento: Article